Combination Immunotherapy With Interferon-gamma and Nivolumab for Patients With Advanced Solid Tumors: A Phase 1 Study

Trial Profile

Combination Immunotherapy With Interferon-gamma and Nivolumab for Patients With Advanced Solid Tumors: A Phase 1 Study

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Interferon gamma (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Feb 2017 According to a Horizon Pharma media release, safety data from the first two cohorts of this trial is presented at the American Society for Clinical Oncology - Society for Immunotherapy of Cancer meeting.
    • 27 Feb 2017 According to a Horizon Pharma media release, safety data from the first two cohorts of this trial are published in a financial report.
    • 07 Nov 2016 According to a Horizon Pharma media release, the enrollment in the second six-patient cohort was completed in September, and the third six-patient cohort is now enrolling.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top